Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice.

Spread the love


. 2020 Dec 4;11:587604.

doi: 10.3389/fphar.2020.587604. eCollection 2020.

Affiliations

Item in Clipboard

Madilyn Coles et al. Front Pharmacol. .

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease that causes behavioral and cognitive impairments. The phytocannabinoid cannabidiol (CBD) has anti-inflammatory, antioxidant, and neuroprotective properties, and in vitro and limited in vivo evidence suggests that CBD possesses therapeutic-like properties for the treatment of AD. Cannabinoids are known to have dose-dependent effects and the therapeutic potential of medium-dose CBD for AD transgenic mice has not been assessed in great detail yet. 12-month-old control and APP Swe/PS1ΔE9 (APPxPS1) transgenic female mice were treated daily via intraperitoneal injection with 5 mg/kg bodyweight CBD (or vehicle) commencing three weeks prior to the assessment of behavioral domains including anxiety, exploration, locomotion, motor functions, cognition, and sensorimotor gating. APPxPS1 mice exhibited a hyperlocomotive and anxiogenic-like phenotype and had wild type-like motor and spatial learning abilities, although AD transgenic mice took generally longer to complete the cheeseboard training (due to a lower locomotion speed). Furthermore spatial learning and reversal learning was delayed by one day in APPxPS1 mice compared to control mice. All mice displayed intact spatial memory and retrieval memory, but APPxPS1 mice showed reduced levels of perseverance in the cheeseboard probe trial. Importantly, vehicle-treated APPxPS1 mice were characterized by object recognition deficits and delayed spatial learning, which were reversed by CBD treatment. Finally, impairments in sensorimotor gating of APPxPS1 mice were not affected by CBD. In conclusion, medium-dose CBD appears to have therapeutic value for the treatment of particular behavioral impairments present in AD patients. Future research should consider the molecular mechanisms behind CBD’s beneficial properties for AD transgenic mice.

Keywords: APPSwe/PS1ΔE9; Alzheimer’s disease; behavior; cannabidiol; transgenic mouse model; treatment.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1

FIGURE 1

Novel object recognition. The percentage of time spent nosing the novel object in the NORT. Data for wild type-like (WT) control and double transgenic APP
Swe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means + SEM. Significant t-test results against chance levels (i.e., 50%) are indicated with “+” (+p < .05 and ++p < .01).

FIGURE 2

FIGURE 2

Spatial learning in the cheeseboard (CB). (A, C, and E) Latency (s) to find the food reward and (B, D, and F) distance traveled (m) during CB training (A and B) averaged across all three trials, (C and D) for intermediate-term memory and (E and F) for reference memory. Data for wild type-like (WT) control and double transgenic APP
Swe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means ± SEM. Significant “genotype” effects are indicated by “*” (*p < .05 and **p < .01) and successful learning is indicated by ‘ ^ ’ (^ ^ ^ p < .001).

FIGURE 3

FIGURE 3

Spatial learning in the reversal cheeseboard (reversal CB). (A, C, and E) Latency (s) to find the food reward and (B, D, and F) distance traveled (m) during reversal CB training (A and B) averaged across all three trials, (C and D) for intermediate-term memory and (E and F) for reference memory. Data for wild type-like (WT) control and double transgenic APP
Swe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means ± SEM. Significant “genotype” effects are indicated by “*” (**p < .01 and ***p < .001) and successful learning is indicated by ‘ ^ ’ (^ ^ ^ p < .001). There was a “time” by “genotype” by “treatment” interaction for distance traveled across all three trials (p = .004) and for intermediate-term memory (p = .04). The “time” by “treatment” interactions for APPxPS1 mice are indicated by “” (p < .05) or the exact trend level has been indicated by “p = .06.”

FIGURE 4

FIGURE 4

Spatial memory in the cheeseboard (CB) probe and reversal cheeseboard (reversal CB) probe. (A) Percentage of time spent (%) in the target zone for the CB probe and (B) for the reversal CB probe. Data for wild type-like (WT) control and double transgenic APP
Swe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means + SEM. Significant t-test results against chance levels (i.e., 12.5%) are indicated by “+” (+p < .05,++p < .01, and +++p < .001).

FIGURE 5

FIGURE 5

Acoustic startle response (ASR) and sensorimotor gating (PPI). (A) ASR to increasing startle pulse intensity (70/100/120 dB), (B) percentage prepulse inhibition (%PPI) averaged over trials for increasing prepulse intensities (74/82/86 dB), and (C) %PPI averaged over prepulse intensity and interstimulus interval (ISI). Data for wild type-like (WT) control and double transgenic APP
Swe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means + SEM. Significant “genotype” effects are indicated with “*” (*p < .05 and **p < .01) and RM effects are indicated by ‘ ^ ’ ( ^ ^ ^ p < .001). There was a “genotype” by “prepulse intensity” interaction for average %PPI for increasing prepulse intensities (p < .001).

Similar articles

References

    1. Arendash G. W., King D. L., Gordon M. N., Morgan D., Hatcher J. M., Hope C. E., et al. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891 (1), 42–53. 10.1016/S0006-8993(00)03186-3 – DOI PubMed
    1. Aso E., Sánchez-Pla A., Vegas-Lozano E., Maldonado R., Ferrer I. (2014). Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J. Alzheimers Dis. 43 (3), 977–991. 10.3233/JAD-141014 – DOI PubMed
    1. Aso E., Andrés-Benito P., Ferrer I. (2016). Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J. Alzheimers Dis. 54 (3), 903–912. 10.3233/JAD-160533 – DOI PubMed
    1. Benito C., Núñez E., Pazos M. R., Tolón R. M., Romero J. (2007). The endocannabinoid system and Alzheimer’s disease. Mol. Neurobiol. 36 (1), 75–81. 10.1007/s12035-007-8006-8 – DOI PubMed
    1. Borchelt D. R., Ratovitski T., van Lare J., Lee M. K., Gonzales V., Jenkins N. A., et al. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (4), 939–945. 10.1016/S0896-6273(00)80974-5 – DOI PubMed

Avatar

Schaka

Related Posts

COVID-19, lockdown, and cannabis use

Expansion of pharmacy preceptors’ cannabidiol knowledge and confidence to ensure patient safety

Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties

Ahead of 4/20, Business and Politicians Take Stock of Cannabis Industry Impact: Week in Review

Signez la pétition !!!

 

840 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories